Insights - Ampio Pharmaceuticals (AMPE) reported results from the botched STEP Study on Tuesday morning, spinning the failed trial of Ampion in osteoarthritis of the knee as positively … Continue Reading
Read NowRecap - Six weeks after Federal Reserve Chairwoman Janet Yellen called biotechnology valuations “substantially stretched” the NASDAQ Biotechnology Index (IBB) is setting new records right alongside the S&P 500. It’s … Continue Reading
Read NowInsights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read NowInsights - Three-year results from EnteroMedics’ (ETRM) DM2 ENABLE Study, a small trial of the company’s VBLOC vagal blocking therapy (delivered via the Maestro System), indicate some positive outcomes in … Continue Reading
Read NowInsights - 12 out of 13 patients receiving an experimental treatment for blood cancer from Kite Pharma (KITE) experienced a response to the treatment, the company said in … Continue Reading
Read NowResearch - Roche (RHHBY) is purchasing InterMune (ITMN) for $8.3B, or $74 per share in cash. Admittedly, this caught me off guard. The world’s leading provider of cancer care products is better known … Continue Reading
Read NowInsights - Regado Biosciences (RGDO) has halted permanently a 13,000-patient phase 3 trial of Revolixys Kit, its two-component anticoagulant system, after serious allergic reactions were seen in the first 3,200 … Continue Reading
Read Now
